PEPTONIC Medical AB: Intends to submit a request for extension of ongoing corporate restructuring
5 juni, 17:40
PEPTONIC Medical AB: Intends to submit a request for extension of ongoing corporate restructuring
PEPTONIC medical AB (publ) (the “Company”) has, as previously communicated, applied for and been granted corporate restructuring by the Uppsala District Court. At the creditors’ meeting on 26 March 2025, the District Court decided that the corporate restructuring may continue until 13 June 2025. During the three initial months of the corporate restructuring, the Company has made progress regarding previously communicated restructuring measures and will, in connection with the Company’s submission of a request for extension of the restructuring, report on these.
A corporate restructuring may not last longer than a total of twelve months, unless the court has previously decided on a plan negotiation. As previously communicated, the corporate restructuring is expected to be completed within three to six months from the application for corporate restructuring. At the creditors' meeting on March 26, 2025, the district court decided that the corporate restructuring may continue until June 13, 2025. During the three initial months of the corporate restructuring, the Company has made progress regarding previously communicated restructuring measures and will, in connection with the Company’s submission of a request for extension of the restructuring, report on these. An extension of the corporate restructuring is a necessary prerequisite for the completion of the measures and the Company therefore intends to submit a request for the corporate restructuring to be extended by a further three months at the beginning of next week.
Complete documents regarding the corporate restructuring are available on the Company's website, www.peptonicmedical.se
For further information please contact:
Anna Linton, CEO of Peptonic Medical AB
E-mail: anna.linton@peptonicmedical.se
Phone: +46 70-244 92 07
About PEPTONIC medical AB
PEPTONIC medical AB (publ) is a pioneering Swedish medtech company specializing in the development and sale of clinically proven self-care products for women’s intimate health. Through its brands VagiVital and Vernivia, the Company offers a broad over-the-counter portfolio of effective and gentle products designed to help women understand, treat, and prevent common medical conditions in the intimate area. Peptonic’s growth strategy centers on geographic expansion, particularly in the U.S. and Europe, while continually enhancing its product portfolio through in-house development and strategic acquisitions.
The company is headquartered in Stockholm, Sweden, and operate the subsidiaries Peptonic medical Inc. and Common Sense Marketing Inc., in the U.S. Peptonic Medical was founded in 2009 and has been listed on the Spotlight Stock Market since 2014.
Ämnen i artikeln
PEPTONIC Medical AB: Intends to submit a request for extension of ongoing corporate restructuring
5 juni, 17:40
PEPTONIC Medical AB: Intends to submit a request for extension of ongoing corporate restructuring
PEPTONIC medical AB (publ) (the “Company”) has, as previously communicated, applied for and been granted corporate restructuring by the Uppsala District Court. At the creditors’ meeting on 26 March 2025, the District Court decided that the corporate restructuring may continue until 13 June 2025. During the three initial months of the corporate restructuring, the Company has made progress regarding previously communicated restructuring measures and will, in connection with the Company’s submission of a request for extension of the restructuring, report on these.
A corporate restructuring may not last longer than a total of twelve months, unless the court has previously decided on a plan negotiation. As previously communicated, the corporate restructuring is expected to be completed within three to six months from the application for corporate restructuring. At the creditors' meeting on March 26, 2025, the district court decided that the corporate restructuring may continue until June 13, 2025. During the three initial months of the corporate restructuring, the Company has made progress regarding previously communicated restructuring measures and will, in connection with the Company’s submission of a request for extension of the restructuring, report on these. An extension of the corporate restructuring is a necessary prerequisite for the completion of the measures and the Company therefore intends to submit a request for the corporate restructuring to be extended by a further three months at the beginning of next week.
Complete documents regarding the corporate restructuring are available on the Company's website, www.peptonicmedical.se
For further information please contact:
Anna Linton, CEO of Peptonic Medical AB
E-mail: anna.linton@peptonicmedical.se
Phone: +46 70-244 92 07
About PEPTONIC medical AB
PEPTONIC medical AB (publ) is a pioneering Swedish medtech company specializing in the development and sale of clinically proven self-care products for women’s intimate health. Through its brands VagiVital and Vernivia, the Company offers a broad over-the-counter portfolio of effective and gentle products designed to help women understand, treat, and prevent common medical conditions in the intimate area. Peptonic’s growth strategy centers on geographic expansion, particularly in the U.S. and Europe, while continually enhancing its product portfolio through in-house development and strategic acquisitions.
The company is headquartered in Stockholm, Sweden, and operate the subsidiaries Peptonic medical Inc. and Common Sense Marketing Inc., in the U.S. Peptonic Medical was founded in 2009 and has been listed on the Spotlight Stock Market since 2014.
Ämnen i artikeln
Analys
-992x558.jpg&w=3840&q=75)
Danmarks nationaldag
-992x558.png&w=3840&q=75)
Fondernas placeringar
-992x558.jpg&w=3840&q=75)
Inflationen
-992x558.jpg&w=3840&q=75)
-992x558.jpg&w=3840&q=75)
Investmentbolag
Analys
Danmarks nationaldag
Fondernas placeringar
Inflationen
Investmentbolag
Marknadsöversikt
1 DAG %
Senast
1 mån
Privatekonomi med Placeras expert
Affärsvärlden
